This is the protocol for a review and there is no abstract. The objectives are as follows:
This 'umbrella' systematic review aims to compare the effectiveness and safety of the three main classes of add-on drugs that are used in later PD. This will involve comparing the efficacy and safety of dopamine agonist, COMTI and MAOBI add-on therapy versus placebo in the management of patients with later PD who are on established levodopa therapy and suffering from motor complications.
Alongside the process of producing the umbrella review, we will perform updates of individual Cochrane adjuvant therapy reviews (Clarke 1999a; Clarke 1999b; Clarke 2000; Clarke 2001a; Clarke 2001b; Deane 2004; van Hilten 1998). Thus, the project will complement previous individual reviews by updating and clarifying the existing evidence base as well as provide important information as to the class effects of add-on therapy in later PD.